Pharma Marketing News
PMN Home | Advertising Information | FAQs
About Us | Contact Us | Privacy Policy
Subscribe Glossary
Pharma Marketing Blog Pharmaguy Audio Podcasts Event Calendar PReader Surveys

Share |

Patients with Chronic Conditions Are OK With Off-Label Drug Promotion
If FDA Allows It, Will Pharma Do It?

The FDA recently held a Part 15 hearing on regarding "Manufacturer Communications Regarding Unapproved Uses of Approved or Cleared Medical Products."

In the notice for this meeting, FDA posed several questions for which it is seeking input at the hearing and afterward. Among these were two questions regarding off-label promotion targeted to patient and consumer audiences.

Results from three different surveys were presented at the hearing on November 9, 2016. Each survey addressed off-label direct-to-consumer (DTC) promotion of drugs by the pharmaceutical industry.

This article summarizes the results of these surveys.

Topics (partial list):
  • What Do Industry Insiders Think?
  • Does FDA Need Help?
  • A Mute Point If Payers Not On Board
  • inVibe Survey of Patients
  • Consumer Reports Survey
  • Will Pharma Do It?
  • Submit Your Comments

Download the full article (PDF file) here:

Further Reading

Issue: Vol. 15, No. 5: December 2016

Find other articles in related Topic Areas:

Vol 15, #5 Contents

Contact Information
Pharma Marketing News

Pharma Marketing News | Subscribe | Industry Insights | Podcasts | Pharmaguy | Blog
Surveys | Glossary | Conference Calendar | Advertising Information | FAQs | About Us | Privacy Policy

© 2016. Pharma Marketing Network. All rights reserved.